Home › Companies › Y-mAbs Therapeutics, Inc. › 2025-2026
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Y-mAbs Therapeutics, Inc.’s Form 8-K, filed July 15, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of July 11, 2025: 3 items on Y-mAbs Therapeutics, Inc.’s Form 8-K, filed July 15, 2025: 2 approved · 1 passed (calculated).
Significant dissent: 1 director (38.7% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Proxy season: 2023-2024 2025-2026
Explore Y-mAbs Therapeutics, Inc. in the interactive database Compare manager voting policies
These tallies are Y-mAbs Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed July 15, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: David N. Gill | 18,926,572 | -- | -- | 11,924,775 | 3,133,377 | 61% | Passed (calculated) | — |
| 2. Ratification of the Appointment of the Independent Registered Public Accounting Firm | 32,884,437 | 1,097,151 | 3,136 | -- | -- | 97% | Approved | — |
| 3. Advisory Vote on the Compensation of the Named Executive Officers | 27,011,027 | 3,838,565 | 1,755 | -- | 3,133,377 | 88% | Approved | — |
Source: Y-mAbs Therapeutics, Inc., Form 8-K, filed with the SEC on July 15, 2025 — read the filing on EDGAR.
See voting trends for Health Care companies, 2025-2026: shareholder support by sector and by company size.
127 asset managers disclosed a vote on at least one Y-mAbs Therapeutics, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 3 wordings of this item as funds reported it.
61% Majority: yes · of votes cast
Description as filed by funds: ELECTION OF CLASS I DIRECTOR: DAVID N. GILL
Y-mAbs Therapeutics, Inc.’s own tally for this item (“Elect Director: David N. Gill”): 18,926,572 for, 11,924,775 withheld, per its Form 8-K filed July 15, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 61% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 48 asset managers below reported 4,263,209 for, 654,760 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,882,029 | 0 | 0 | 0 | For |
| BlackRock | 1,331,865 | 0 | 0 | 0 | For |
| Fidelity | 517,346 | 0 | 0 | 0 | For |
| Charles Schwab | 279,183 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 234,022 | Withhold |
| Federated Hermes | 101,334 | 0 | 0 | 0 | For |
| Equitable | 46,936 | 0 | 0 | 34,620 | Mixed |
| Goldman Sachs | 0 | 0 | 0 | 55,809 | Withhold |
| TIAA | 50,320 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 0 | 0 | 0 | 42,025 | Withhold |
| ALPS ETF Trust | 0 | 0 | 0 | 31,990 | Withhold |
| Lincoln Financial | 0 | 0 | 0 | 28,854 | Withhold |
| Northern Trust | 0 | 0 | 0 | 27,419 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 26,265 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 0 | 0 | 0 | 24,900 | Withhold |
| Global X | 0 | 0 | 0 | 20,117 | Withhold |
| AIG/SunAmerica | 0 | 0 | 0 | 18,654 | Withhold |
| PACE SELECT ADVISORS TRUST | 0 | 0 | 0 | 17,100 | Withhold |
| HC CAPITAL TRUST | 0 | 0 | 0 | 14,136 | Withhold |
| CLEARWATER INVESTMENT TRUST | 0 | 0 | 0 | 13,239 | Withhold |
| Brighthouse | 0 | 0 | 0 | 12,799 | Withhold |
| John Hancock | 0 | 0 | 0 | 12,203 | Withhold |
| Pacific Life | 11,982 | 0 | 0 | 0 | For |
| Voya | 0 | 0 | 0 | 10,211 | Withhold |
| ProShares | 0 | 0 | 0 | 8,587 | Withhold |
Showing the 25 largest of 48 asset managers. All 48 are in the interactive database (link above).
Combines 6 wordings of this item as funds reported it.
88% Approved · of votes cast
Description as filed by funds: TO APPROVE, ON A NON-BINDING ADVISORY VOTE BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS AS DISCLOSED IN THE PROXY STATEMENT.
Y-mAbs Therapeutics, Inc.’s own tally for this item (“3. Advisory Vote on the Compensation of the Named Executive Officers”): 27,011,027 for, 3,838,565 against — passed, per its Form 8-K filed July 15, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 3 – Advisory Vote on the Compensation of the Named Executive Officers The Company's stockholders approved Proposal 3.”
Support: 88% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,882,029 | 0 | 0 | 0 | For |
| BlackRock | 1,331,865 | 0 | 0 | 0 | For |
| Fidelity | 517,346 | 0 | 0 | 0 | For |
| Charles Schwab | 279,183 | 0 | 0 | 0 | For |
| Dimensional | 0 | 234,022 | 0 | 0 | Against |
| Federated Hermes | 101,334 | 0 | 0 | 0 | For |
| Equitable | 81,556 | 0 | 0 | 0 | For |
| Goldman Sachs | 55,809 | 0 | 0 | 0 | For |
| TIAA | 50,320 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 42,025 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 31,990 | 0 | 0 | 0 | For |
| Lincoln Financial | 27,300 | 1,554 | 0 | 0 | Mixed |
| Northern Trust | 27,419 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 26,265 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 24,900 | 0 | 0 | 0 | For |
| Global X | 20,117 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 18,654 | 0 | 0 | 0 | For |
| PACE SELECT ADVISORS TRUST | 17,100 | 0 | 0 | 0 | For |
| HC CAPITAL TRUST | 14,136 | 0 | 0 | 0 | For |
| CLEARWATER INVESTMENT TRUST | 13,239 | 0 | 0 | 0 | For |
| Brighthouse | 12,799 | 0 | 0 | 0 | For |
| John Hancock | 12,203 | 0 | 0 | 0 | For |
| Pacific Life | 11,982 | 0 | 0 | 0 | For |
| Voya | 10,211 | 0 | 0 | 0 | For |
| ProShares | 8,587 | 0 | 0 | 0 | For |
Fund voting reports, all 48 managers: 4,668,807 for, 249,162 against. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Paradigm Biocapital Advisors LP | 4,031,230 | 0 | 0 | 0 | For |
| Polar Capital Holdings Plc | 3,012,000 | 0 | 0 | 0 | For |
| Caligan Partners LP | 2,292,049 | 0 | 0 | 0 | For |
| BlackRock | 1,102,177 | 0 | 0 | 0 | For |
| BOOTHBAY FUND MANAGEMENT, LLC | 643,133 | 0 | 0 | 0 | For |
| Sofinnova Investments, Inc. | 590,000 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 583,723 | 0 | 0 | 0 | For |
| State Street | 561,870 | 0 | 0 | 0 | For |
| UniSuper Management Pty Ltd | 325,000 | 0 | 0 | 0 | For |
| Soleus Capital Management, L.P. | 323,618 | 0 | 0 | 0 | For |
| Stonepine Capital Management, LLC | 300,000 | 0 | 0 | 0 | For |
| Charles Schwab | 279,189 | 0 | 0 | 0 | For |
| DE Shaw | 275,747 | 0 | 0 | 0 | For |
| Nantahala Capital Management, LLC | 234,722 | 0 | 0 | 0 | For |
| Two Sigma | 184,237 | 0 | 0 | 0 | For |
| Citadel | 173,950 | 0 | 0 | 0 | For |
| Northern Trust | 159,525 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 114,329 | 0 | 0 | 0 | For |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 112,268 | 0 | 0 | 0 | For |
| Federated Hermes | 109,063 | 0 | 0 | 0 | For |
| RICE HALL JAMES & ASSOCIATES, LLC | 97,864 | 0 | 0 | 0 | For |
| Vanguard | 95,554 | 0 | 0 | 0 | For |
| AQR | 68,141 | 0 | 0 | 0 | For |
| AllianceBernstein | 54,780 | 0 | 0 | 0 | For |
| Nuveen | 51,191 | 0 | 0 | 0 | For |
Institutional-manager reports, all 97 managers: 16,157,961 for, 76,748 against. Showing the 25 largest; every one is in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
97% Approved · of votes cast
Description as filed by funds: To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2025.
Y-mAbs Therapeutics, Inc.’s own tally for this item (“2. Ratification of the Appointment of the Independent Registered Public Accounting Firm”): 32,884,437 for, 1,097,151 against — passed, per its Form 8-K filed July 15, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 2 – Ratification of the Appointment of the Independent Registered Public Accounting Firm The Company's stockholders approved Proposal 2.”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 47 asset managers below reported 4,903,833 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,882,029 | 0 | 0 | 0 | For |
| BlackRock | 1,331,865 | 0 | 0 | 0 | For |
| Fidelity | 517,346 | 0 | 0 | 0 | For |
| Charles Schwab | 279,183 | 0 | 0 | 0 | For |
| Dimensional | 234,022 | 0 | 0 | 0 | For |
| Federated Hermes | 101,334 | 0 | 0 | 0 | For |
| Equitable | 81,556 | 0 | 0 | 0 | For |
| Goldman Sachs | 55,809 | 0 | 0 | 0 | For |
| TIAA | 50,320 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 42,025 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 31,990 | 0 | 0 | 0 | For |
| Lincoln Financial | 28,854 | 0 | 0 | 0 | For |
| Northern Trust | 27,419 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 26,265 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 24,900 | 0 | 0 | 0 | For |
| Global X | 20,117 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 18,654 | 0 | 0 | 0 | For |
| PACE SELECT ADVISORS TRUST | 17,100 | 0 | 0 | 0 | For |
| CLEARWATER INVESTMENT TRUST | 13,239 | 0 | 0 | 0 | For |
| Brighthouse | 12,799 | 0 | 0 | 0 | For |
| John Hancock | 12,203 | 0 | 0 | 0 | For |
| Pacific Life | 11,982 | 0 | 0 | 0 | For |
| Voya | 10,211 | 0 | 0 | 0 | For |
| ProShares | 8,587 | 0 | 0 | 0 | For |
| Jackson National | 8,406 | 0 | 0 | 0 | For |
Showing the 25 largest of 47 asset managers. All 47 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 43,882,638 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 4.29% |
| 2 | BlackRock | 3.04% |
| 3 | Fidelity | 1.18% |
| 4 | Charles Schwab | 0.64% |
| 5 | Dimensional | 0.53% |
| 6 | Federated Hermes | 0.23% |
| 7 | Equitable | 0.19% |
| 8 | Goldman Sachs | 0.13% |
| 9 | TIAA | 0.11% |
| 10 | ETFis Series Trust I | 0.10% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Paradigm Biocapital Advisors LP | 9.19% |
| 2 | Polar Capital Holdings Plc | 6.86% |
| 3 | Caligan Partners LP | 5.22% |
| 4 | BlackRock | 2.51% |
| 5 | BOOTHBAY FUND MANAGEMENT, LLC | 1.47% |
| 6 | Sofinnova Investments, Inc. | 1.34% |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 1.33% |
| 8 | State Street | 1.28% |
| 9 | UniSuper Management Pty Ltd | 0.74% |
| 10 | Soleus Capital Management, L.P. | 0.74% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| Johan Wedell‑Wedellsborg | 4,715,553 | 10.75% | Proxy statement (DEF 14A), table as of May 23, 2025 |
| Dr. James I. Healy | 2,314,598 | 5.27% | Proxy statement (DEF 14A), table as of May 23, 2025 |
| Thomas Gad | 1,339,282 | 3.05% | Proxy statement (DEF 14A), table as of May 23, 2025 |
| Michael Rossi | 339,993 | 0.77% | Proxy statement (DEF 14A), table as of May 23, 2025 |
| Dr. Ashutosh Tyagi | 120,320 | 0.27% | Proxy statement (DEF 14A), table as of May 23, 2025 |
| David N. Gill | 112,320 | 0.26% | Proxy statement (DEF 14A), table as of May 23, 2025 |
| Laura J. Hamill | 88,320 | 0.20% | Proxy statement (DEF 14A), table as of May 23, 2025 |
| Peter Pfreundschuh | 57,833 | 0.13% | Proxy statement (DEF 14A), table as of May 23, 2025 |
| Dr. Mary Tagliaferri | 32,373 | 0.07% | Proxy statement (DEF 14A), table as of May 23, 2025 |
Percentages above are of 43,882,638 shares outstanding, as reported by Y-mAbs Therapeutics, Inc. on its Form 10-Q dated April 30, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At Y-mAbs Therapeutics, Inc.'s shareholder meeting held July 11, 2025, in the 2025-2026 proxy season, 127 asset managers reported votes on at least one of its 3 ballot items in their SEC Form N-PX filings, covering 488 separate fund positions. On the most widely held item on that ballot — TO APPROVE, ON A NON-BINDING ADVISORY VOTE BASIS, THE COMPENSATION OF THE COMPANY'S NAMED… — Y-mAbs Therapeutics, Inc.'s filing reports the proposal as approved, with 88% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Y-mAbs Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on July 15, 2025.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Y-mAbs Therapeutics, Inc.’s 10-Q dated April 30, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
Y-mAbs Therapeutics, Inc. proxy season coverage: 2023-2024 · 2025-2026 (this page).
Proxy Votes Now, “Y-mAbs Therapeutics, Inc. 2025 Annual Meeting (2025-2026 season)”, https://proxyvotesnow.com/company/y-mabs-therapeutics-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.